Recommended Dosage of Levosalbutamol (Syr Ascoril LS Junior) for a 7-Month-Old Child
For a 7-month-old child, the recommended dosage of Levosalbutamol (Syr Ascoril LS Junior) should be calculated based on weight at 3 mg/kg per dose, given twice daily. 1
Dosage Calculation Principles
- For infants under 12 months of age, careful weight-based dosing is essential to avoid adverse effects 1
- For children weighing less than 15 kg, dosing should be calculated by weight rather than using standard fixed doses 1
- The medication should be administered using the provided measuring device to ensure accurate dosing 1
Administration Guidelines
- The medication should be given at evenly spaced intervals throughout the day to maintain consistent therapeutic levels 1
- For infants, the syrup formulation is preferred over other delivery methods due to ease of administration 2
- Administer the medication consistently at the same times each day to maintain therapeutic effect 1
Safety Considerations
- Levosalbutamol has a more favorable safety profile compared to racemic salbutamol (albuterol) in pediatric patients 3, 4
- Lower doses of levosalbutamol have demonstrated efficacy comparable to higher doses of racemic albuterol while causing fewer side effects 4
- Common side effects to monitor for include tremor (1%), palpitations (0.9%), and vomiting (0.7%), which are typically mild and transient 2
Monitoring
- Observe for clinical improvement in respiratory symptoms within 48-72 hours of starting therapy 1
- If symptoms worsen or do not improve within 72 hours, medical reevaluation is necessary 1
- Monitor heart rate and respiratory rate before and after administration to assess response and detect potential adverse effects 5
Clinical Efficacy
- Levosalbutamol has been shown to be effective for respiratory conditions in both adults and children 2
- Studies have demonstrated that levosalbutamol causes less tachycardia compared to racemic salbutamol while providing equivalent or superior bronchodilation 5
- The R-isomer in levosalbutamol is the therapeutically active component, while avoiding potential adverse effects associated with the S-isomer present in racemic formulations 3